Editor's Pick Featured Share Your Research

Peter Canning

My name is Peter Canning. I’m a scientist, currently a postdoctoral research associate currently based at the Weatherall Institute of Molecular Medicine, University of Oxford. I have previously worked at the University of Warwick and the Oxford division of the Structural Genomics Consortium. My research uses structural and biochemical methods to understand proteins involved in disease and design new drugs to target them. I also like writing about science and making illustrations.

Clinical Cancer Drugs Identified As Inhibitors Of Inflammatory Signaling

Imatinib (sold as Gleevec) is a breakthrough cancer drug approved in 2001 for the treatment of Chronic Myeloid Leukaemia (CML).  It was designed to inhibit the BCR/ABL fusion protein, a constitutively active version of the kinase ABL, that was found […]